Lumipulse - Fujirebio
In 1992, we launched one of the world's first fully automated chemiluminescent enzyme immunoassay (CLEIA) instruments - the very first LUMIPULSE - in Japan. Today, we are the second largest immunoassay instrument supp...
Searching…
In 1992, we launched one of the world's first fully automated chemiluminescent enzyme immunoassay (CLEIA) instruments - the very first LUMIPULSE - in Japan. Today, we are the second largest immunoassay instrument supp...
Oct 17, 2025 · Lumipulse is a test that acts as an early detector for Alzheimer’s disease. It helps persons 55 and over determine in an inexpensive, non-invasive way if they have the benchmarkers for Alzheimer’s. This...
通过这项研究,我们希望评估血浆 Aβ40、Aβ42 和 p-tau181 的性能,以使用自动化 Lumipulse 平台检测 CSF 病理变化。 血浆和脑脊液 Aβ40、Aβ42 和 p-tau181 均在 208 名认知未受损受试者(其中 30.3% 为 ApoE4 携带者)中进行了评估。
本文详细介绍了Lumipulse平台的主要特点、在阿尔茨海默病检测中的应用以及其他诊断领域的应用。 通过了解这些信息,读者可以更加深入地了解Lumipulse平台在临床诊断中的重要性和价值。
Dec 25, 2023 · Fujirebio Holdings, Inc.总裁兼首席执行官Goki Ishikawa表示: “在我们的全自动LUMIPULSE平台上推出pTau 217血浆测定是Fujirebio为全球实验室和临床医生提供新颖、创新的神经退行性疾病生物标记物所迈出的重要一步。
The LUMIPULSE G1200 is a robust mid-sized fully automated immunoassay instrument from the already widely successful LUMIPULSE G series. The LUMIPULSE G1200 uses a unique mono test cartridge concept and among many othe...
神经生物标志物-项目简介 LUMIPULSE G1200全自动免疫分析仪与配套神经变性病生物标志物检测试剂 —为临床诊断而设计的仪器平台及配套试剂 LUMIPULSE G1200 (Fujirebio)已通过欧洲CE-IVDR和美国FDA注册 (注册号1643621)。仪器经过十余年的临床使用、迭代更新及性能提升,目前广泛应用于包括神经变性病生物标志 ...
Dec 25, 2023 · Fujirebio Holdings, Inc.总裁兼首席执行官Goki Ishikawa表示: “在我们的全自动LUMIPULSE平台上推出pTau 217血浆测定是Fujirebio为全球实验室和临床医生提供新颖、创新的神经退行性疾病生物标记物所迈出的重要一步。
May 19, 2025 · The FDA-cleared Lumipulse Plasma Ratio blood test for the early detection of amyloid plaques associated with Alzheimer's disease (AD).
Immunoassay to be used with the automated LUMIPULSE G System for the quantitative measurement of neurofilament light (NfL) in human plasma and serum. This product is not for use in diagnostic procedures, for ‘Research...